China’s Biotech Revolution

AI’s enormous capital requirements are reshaping the way companies tap credit markets. Our Chief Fixed Income Strategist Vishy Tirupattur takes stock of this summer’s key financing developments. Read more insights from Morgan Stanley.----- Transcript -----Vishy Tirupattur: Welcom ...  Show more

AI is becoming a matter of national strategy, as countries seek more control over their own technology. Our Heads of U.S. Public Policy Ariana Salvatore and Global Thematic Research Stephen Byrd look at the race for AI sovereignty and its implications for investors.Read more insi ...  Show more

China is fast becoming a major player in the global pharmaceutical and biotech industries. Once focused primarily on generic and me-too drugs, Chinese companies are now making headlines with innovative breakthroughs in oncology and gene therapy. Foreign investors are taking notic ...  Show more

China’s biotech industry is booming. Driven by vast government funding and Western partnerships, the country is introducing new commercial drugs at a faster pace than ever before. But could controversial topics such as human genetic engineering derail its accelerated growth? Shan ...  Show more

In the last few decades, China has gone from technological scarcity to abundance. What sparked this shift? Economist Keyu Jin explores how China has fostered a model of innovation unlike any other and shows why understanding its competitive, collaborative approach could benefit t ...  Show more

Private markets have grown significantly over the past few years, fueled by scientific breakthroughs and technological innovation. Our experts discuss biotechnology, artificial intelligence and healthcare valuation trends, how venture capitalists and startups are navigating the c ...  Show more